274 related articles for article (PubMed ID: 24145083)
21. [Anti-TNF alpha in the treatment of rheumatoid arthritis and ankylosing spondylitis].
Lanfant-Weybel K; Lequerré T; Vittecoq O
Presse Med; 2009 May; 38(5):774-87. PubMed ID: 19327945
[TBL] [Abstract][Full Text] [Related]
22. Treatment of ankylosing spondylitis with TNF inhibitors does not have adverse effect on results of liver function tests: a longitudinal study.
Capkin E; Karkucak M; Cosar AM; Ak E; Karaca A; Gokmen F; Budak BS; Tosun M
Int J Rheum Dis; 2015 Jun; 18(5):548-52. PubMed ID: 24612551
[TBL] [Abstract][Full Text] [Related]
23. The change of bone mineral density according to treatment agents in patients with ankylosing spondylitis.
Kang KY; Lee KY; Kwok SK; Ju JH; Park KS; Hong YS; Kim HY; Park SH
Joint Bone Spine; 2011 Mar; 78(2):188-93. PubMed ID: 20621536
[TBL] [Abstract][Full Text] [Related]
24. [Serum metalloproteinase-3 levels in assessing efficacy of Etanercept in patients with ankylosing spondylitis].
Wang QH; Zhang SZ; Xue J; Wu HX
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2010 Jul; 39(4):409-14. PubMed ID: 20731042
[TBL] [Abstract][Full Text] [Related]
25. The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients.
Seitz M; Wirthmüller U; Möller B; Villiger PM
Rheumatology (Oxford); 2007 Jan; 46(1):93-6. PubMed ID: 16720636
[TBL] [Abstract][Full Text] [Related]
26. Increased levels of asymmetric dimethylarginine (ADMA) in patients with ankylosing spondylitis.
Sari I; Kebapcilar L; Alacacioglu A; Bilgir O; Yildiz Y; Taylan A; Yuksel A; Kozaci DL
Intern Med; 2009; 48(16):1363-8. PubMed ID: 19687580
[TBL] [Abstract][Full Text] [Related]
27. The effect of smoking on response and drug survival in rheumatoid arthritis patients treated with their first anti-TNF drug.
Söderlin MK; Petersson IF; Geborek P
Scand J Rheumatol; 2012 Feb; 41(1):1-9. PubMed ID: 22118371
[TBL] [Abstract][Full Text] [Related]
28. Responsiveness of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumour necrosis factor alpha inhibitors.
Pedersen SJ; Sørensen IJ; Hermann KG; Madsen OR; Tvede N; Hansen MS; Thamsborg G; Andersen LS; Majgaard O; Loft AG; Erlendsson J; Asmussen K; Johansen JS; Jurik AG; Møller J; Hasselquist M; Mikkelsen D; Skjødt T; Hansen A; Ostergaard M
Ann Rheum Dis; 2010 Jun; 69(6):1065-71. PubMed ID: 19740906
[TBL] [Abstract][Full Text] [Related]
29. Anti-tumour necrosis factor treatment increases circulating T helper type 17 cells similarly in different types of inflammatory arthritis.
Hull DN; Williams RO; Pathan E; Alzabin S; Abraham S; Taylor PC
Clin Exp Immunol; 2015 Sep; 181(3):401-6. PubMed ID: 25766640
[TBL] [Abstract][Full Text] [Related]
30. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis.
Brandt J; Khariouzov A; Listing J; Haibel H; Sörensen H; Grassnickel L; Rudwaleit M; Sieper J; Braun J
Arthritis Rheum; 2003 Jun; 48(6):1667-75. PubMed ID: 12794835
[TBL] [Abstract][Full Text] [Related]
31. Effects of anti-TNF therapy on glucose metabolism in patients with ankylosing spondylitis, psoriatic arthritis or juvenile idiopathic arthritis.
da Silva BS; Bonfá E; de Moraes JC; Saad CG; Ribeiro AC; Gonçalves CR; de Carvalho JF
Biologicals; 2010 Sep; 38(5):567-9. PubMed ID: 20638299
[TBL] [Abstract][Full Text] [Related]
32. Effect of therapeutic inhibition of TNF on circulating endothelial progenitor cells in patients with rheumatoid arthritis.
Spinelli FR; Metere A; Barbati C; Pierdominici M; Iannuccelli C; Lucchino B; Ciciarello F; Agati L; Valesini G; Di Franco M
Mediators Inflamm; 2013; 2013():537539. PubMed ID: 24222719
[TBL] [Abstract][Full Text] [Related]
33. Drug survival rates of tumor necrosis factor inhibitors in patients with rheumatoid arthritis and ankylosing spondylitis.
Kang JH; Park DJ; Lee JW; Lee KE; Wen L; Kim TJ; Park YW; Lee SS
J Korean Med Sci; 2014 Sep; 29(9):1205-11. PubMed ID: 25246737
[TBL] [Abstract][Full Text] [Related]
34. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis.
Rudwaleit M; Listing J; Brandt J; Braun J; Sieper J
Ann Rheum Dis; 2004 Jun; 63(6):665-70. PubMed ID: 15037444
[TBL] [Abstract][Full Text] [Related]
35. Remission in ankylosing spondylitis treated with anti-TNF-α drugs: a national multicentre study.
Spadaro A; Lubrano E; Marchesoni A; D'Angelo S; Ramonda R; Addimanda O; Perrotta FM; Olivieri I; Punzi L; Salvarani C
Rheumatology (Oxford); 2013 Oct; 52(10):1914-9. PubMed ID: 23878312
[TBL] [Abstract][Full Text] [Related]
36. Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents.
Gao X; Wendling D; Botteman MF; Carter JA; Rao S; Cifaldi M
J Med Econ; 2012; 15(6):1054-63. PubMed ID: 22563743
[TBL] [Abstract][Full Text] [Related]
37. Effect of total arthroplasty combined with anti-tumor necrosis factor agents in attenuating systemic disease activity in patients with rheumatoid arthritis.
Hayashi M; Kojima T; Funahashi K; Kato D; Matsubara H; Shioura T; Kanayama Y; Hirano Y; Ishiguro N
Mod Rheumatol; 2012 Jun; 22(3):363-9. PubMed ID: 21979824
[TBL] [Abstract][Full Text] [Related]
38. Anti-nuclear antibodies, anti-DNA and C4 complement evolution in rheumatoid arthritis and ankylosing spondylitis treated with TNF-alpha blockers.
Gonnet-Gracia C; Barnetche T; Richez C; Blanco P; Dehais J; Schaeverbeke T
Clin Exp Rheumatol; 2008; 26(3):401-7. PubMed ID: 18578960
[TBL] [Abstract][Full Text] [Related]
39. The effect of anti-tumor necrosis factor (TNF)-alpha therapy with etanercept on endothelial functions in patients with rheumatoid arthritis.
Tikiz H; Arslan O; Pirildar T; Tikiz C; Bayindir P
Anadolu Kardiyol Derg; 2010 Apr; 10(2):98-103. PubMed ID: 20382605
[TBL] [Abstract][Full Text] [Related]
40. Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire.
Barra L; Pope JE; Payne M
J Rheumatol; 2009 Jul; 36(7):1421-8. PubMed ID: 19487267
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
